ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1070

Mortality Risk in Patients with Rheumatoid Arthritis Who Develop Non–Hodgkin′s Lymphoma

Pratibha Nayak1, Zaki Abou Zahr2, Ruili Luo3, Linda Elting3 and Maria E. Suarez-Almazor4, 1General Internal Medicine, The University of Texas, MD Anderson Cancer Center, Houston, TX, 2Rheumatology, Baylor College of Medicine, Houston, TX, 3The Department of Health Services Research, The University of Texas, MD Anderson Cancer Center, Houston, TX, 4The Department of General Internal Medicine, The University of Texas, MD Anderson Cancer Center, Houston, TX

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: cancer and registry, Medicare

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Epidemiology and Public Health (ACR): Rheumatoid Arthritis and Systemic Lupus Erythematosus Outcomes

Session Type: Abstract Submissions (ACR)

Background/Purpose

Patients with rheumatoid arthritis (RA) have greater risk of non-Hodgkin lymphoma (NHL) than the general population. A previous two-center study suggested that the rates of progression and relapse of patients with NHL and antecedent RA were better than those  of patients with NHL alone, but that the overall risk of mortality was increased. The objective of this study was to conduct a population-based study of Medicare beneficiaries to compare the survival of patients with NHL and prior RA with that of patients with NHL alone. 

Methods

We used for this study population-based data that links patients with cancer in the State of Texas (Texas Cancer Registry) with Medicare data in beneficiaries 65 years and older. The datafile has a case capture of over 95%. We included all Medicare-linked cases in the registry diagnosed with NHL (B cell, T cell, or not otherwise specified/unknown lineage) between 2001 and 2010. We classified each patient into one of three groups based on RA Medicare claims during the year prior to cancer diagnosis (International Classification of Diseases ICD 9, code 714): (i) 1-RA (having least one RA claim), (ii) 2-RA (having at least 2 hospital or outpatient claims, 6 or more months apart), and (iii) no-RA (having no claims related to RA). Cox proportional hazards regression models were used to compare overall survival among groups. Covariates included demographic variables, stage at diagnosis and comorbidity burden estimated using the Charlson’s comorbidity index.

Results

8,858 NHL patients were included, of whom 2.5% (n=226) had 1-RA claim and 2.3% (n=203) had 2-RA claims. Overall median survival for the cohort was close to 4 years. The hazard ratio (HR) for patients in the 1-RA group was 1.14 (95% CI, 0.95-1.37), and that for the 2-RA group was 1.04 (95% CI, 0.85-1.27), compared to that of patients without RA after controlling for demographics, and stage. The risk did not significantly change after including comorbidity in the models: 1-RA group HR=1.13, 95% CI, 0.94-1.36, and 2-RA group HR=1.04, 95% CI, 0.85-1.26. Comorbidity was an independent factor significantly associated with mortality such that having one additional comorbidity increased risk by 20% HR=1.20, (95% CI, 1.12-1.29), and having 3 or more comorbidities increased risk by more than 2 fold, HR=2.31 (95% CI, 2.01-2.43). 

Conclusion

Having antecedent RA does not confer an independent mortality risk in NHL Medicare beneficiaries. However, patients with RA and NHL with other comorbidities can have decreased survival. Additional research should evaluate the risk associated with specific comorbid conditions, and whether this potential detrimental effect is from disease burden or differential use of cancer therapies.


Disclosure:

P. Nayak,
None;

Z. Abou Zahr,
None;

R. Luo,
None;

L. Elting,
None;

M. E. Suarez-Almazor,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/mortality-risk-in-patients-with-rheumatoid-arthritis-who-develop-non-hodgkin%e2%80%b2s-lymphoma/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology